Evotec: High tension - | important date ahead:
Evotec shares rise; 9-month figures and outlook expected; expanded partnership with Bristol Myers Squibb and Novo ...
deraktionaer.de/artikel/pharma-biotech/evotec-hochspannung-wichtiger-termin-voraus-20369311.html
Story Details
| Last Updated | |
| Total Articles | 1 |
Main Topics
single unit of ownership in a corporation, mutual fund, or any other organization
Similar to This
Previous
Evotec stock is being dismantled – | losses of up to €105 million are looming: Evotec has drastically lowered its annual targets. Instead of operating profit ...
wallstreet-online.de/nachricht/21106147-viertel-boersenwert-futsch-evotec-aktie-zerlegt-105-millionen-euro-verlust-drohen
Evotec: Analyst sees 125 percent share price potential - | The details: Evotec struggles financially, receives milestone payments and BARDA deal; Berenberg ...
deraktionaer.de/artikel/pharma-biotech/evotec-analyst-sieht-125-prozent-kurschance-die-details-20398004.html
Evotec: Milestone for pharmaceutical giant - | Stock shows signs of life: Evotec receives $5 million from Bristol Myers Squibb.
deraktionaer.de/artikel/pharma-biotech/evotec-meilenstein-von-pharma-giganten-aktie-sendet-lebenszeichen-20390208.html
Evotec: Share at the top of the MDAX - | this is the reason: Evotec plans to sell biologics site to Sandoz for $300 million to promote capital-light model.
deraktionaer.de/artikel/pharma-biotech/evotec-aktie-an-mdax-spitze-das-ist-der-grund-20384104.html
Evotec: Share price collapses massively - | what's going on?: Evotec share price plummets after lowered sales forecast; EBITDA targets remain the same.
deraktionaer.de/artikel/pharma-biotech/evotec-aktie-bricht-massiv-ein-was-ist-da-los-20383542.html
Evotec jumps share price - | strongest stock in the MDAX ahead of Traton and Bilfinger
deraktionaer.de/artikel/pharma-biotech/evotec-mit-kurssprung-staerkster-wert-im-mdax-vor-traton-und-bilfinger-20380744.html
Evotec with figures - | Share price plunges again: Evotec reports Q1 revenue decline, confirms annual targets and long-term outlook until 2028.
deraktionaer.de/artikel/pharma-biotech/evotec-mit-zahlen-aktie-taucht-erneut-ab-20379514.html
Evotec: Good News - | Share Gains Again: Evotec shares rise following progress in the cooperation with Bristol Myers Squibb and a positive annual report.
deraktionaer.de/artikel/pharma-biotech/evotec-gute-news-aktie-gibt-erneut-gas-20378875.html
Evotec: Two important dates: Evotec could soon be promoted to the MDAX, while Befesa could be relegated to the SDAX and SMA Solar could be replaced by Ionos in ...
deraktionaer.de/artikel/pharma-biotech/evotec-zwei-wichtige-termine--20371140.html
Is the situation with Evotec shares getting worse? Investors now have one alternative
boerse-online.de/nachrichten/aktien/wird-die-lage-bei-der-evotec-aktie-immer-schlimmer-anleger-haben-jetzt-1-alternative-20370889.html
San Diego’s Halozyme withdraws $2.1B Evotec bid, just one week after making offer
sandiegouniontribune.com/2024/11/22/san-diegos-halozyme-withdraws-proposed-2-1b-acquisition-of-evotec/
Key FactsEvotec's MDAX Comeback on the Horizon
Nov 22, 2024 · Reading time: ~30 sec.
Summary created with AI assistance · Source: deraktionaer.de
Summary created with AI assistance · Source: deraktionaer.de
- Evotec may be poised for a return to the MDAX by the end of the year, as JPMorgan predicts the company's inclusion in the mid-cap index.
- Halozyme Therapeutics has made a takeover offer for Evotec at 11 euros per share, valuing the company at around two billion euros.
- Despite the stock briefly rising to 10.69 euros, it is currently hovering around the 10-euro mark, while Evotec aims to resist the takeover attempt.
- For a successful deal, higher bids will be necessary, and Evotec must regain investor confidence to ensure long-term success.
Evotec: Extreme Ausschläge: Evotec shares lose over 50% on an annual basis, but recover with 51.9% in a 1-month comparison as the SDAX leader.
deraktionaer.de/artikel/pharma-biotech/evotec-extreme-ausschlaege-20370001.html
Key FactsEvotec: Stock Shows Extreme Transformation
Nov 14, 2024 · Reading time: ~30 sec.
Summary created with AI assistance · Source: deraktionaer.de
Summary created with AI assistance · Source: deraktionaer.de
- Evotec's stock experienced a significant decline of over 50% last year but is now the top SDAX performer with a 51.9% monthly increase.
- New CEO Christian Wojczewski announced progress on strategic initiatives aimed at long-term growth.
- Speculation of a takeover arose as Triton acquired 9.16% of Evotec's voting rights, although the company denied any discussions.
- Regaining investor confidence is crucial for Evotec, which needs to deliver important news in the coming months.
Evotec: Deep red figures - | Shares in free fall again: Evotec is struggling with falling sales and increasing losses, but remains optimistic due to new ...
deraktionaer.de/artikel/aktien/evotec-tiefrote-zahlen-aktie-wieder-im-freien-fall-20369522.html
Evotec before the figures: The tension is rising - | will the rally continue?: Evotec sells production facility, focuses on profitable growth and expects ...
deraktionaer.de/artikel/aktien/evotec-vor-den-zahlen-die-spannung-steigt-geht-die-rally-weiter-20369405.html
Evotec: New deal with Bristol Myers - | Evotec shares rise by eleven percent: Evotec is intensifying its collaboration with its US partner Bristol Myers ...
handelsblatt.com/finanzen/maerkte/aktien/evotec-neuer-deal-mit-bristol-myers-evotec-aktie-steigt-um-elf-prozent/100081385.html
Paid articlePaywall Evotec scores with Novo Nordisk cooperation - | Analyst recommends buying: Evotec shares rise after partnership with Novo Nordisk and positive analyst comment.
deraktionaer.de/artikel/pharma-biotech/evotec-punktet-mit-novo-nordisk-kooperation-analyst-raet-zum-kauf-20367125.html
Evotec: Important dates in the coming week: Evotec shares remain weak; CEO Wojczewski buys shares; company drops from MDAX.
deraktionaer.de/artikel/pharma-biotech/evotec-wichtige-termine-in-der-kommenden-woche-20366697.html
Evotec: "Sell" twice: Evotec shares stabilize after price slide near €6, analysts remain skeptical.
deraktionaer.de/artikel/aktien/evotec-zweimal-verkaufen-20364246.html
Evotec on course for recovery: BMS deal pays off: Evotec shares rebound on positive news from its partnership with Bristol Myers Squibb ...
deraktionaer.de/artikel/pharma-biotech/evotec-auf-erholungskurs-bms-deal-zahlt-sich-aus-20347082.html
Next